system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, PATIENTS AND METHODS, RESULTS. Meshes: Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Female, Humans, Immunohistochemistry, Male, Middle Aged, Proto-Oncogene Proteins c-bcl-2, Stomach Neoplasms, Survival Rate, Tumor Suppressor Protein p53.
user
Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors? Context: The prognostic value of p53 and bcl-2 protein expressions in gastric cancer is still unclear, as shown by the discordant results still reported in the literature. In this study, p53 and bcl-2 protein expressions were investigated by immunohistochemistry and correlated with various clinicopathological parameters and survival, in a series of 52 gastric cancer patients who underwent potentially curative gastrectomy. p53 expression was observed in 34 patients (65.4%) and was significantly correlated with the intestinal type of cancer (p=0.018). Bcl-2 expression was detected in 12 patients (23.1%) and inversely correlated with lymph node metastasis (p=0.042) and tumour grade (p=0.024). There was a statistically significant inverse relationship between p53 and bcl-2 expression (p=0.014). Moreover, p53 and bcl-2 protein expressions had no significant influence on overall survival.
assistant
These results suggest that the expression of p53 and bcl-2 proteins has no significant impact on the outcome of patients with gastric cancer.